
GSK acquires Sierra Oncology for 1.9bn
GSK is paying $1.9 bn in cash ($55 per share) for the deal. This is a 39 per cent premium to the Sierra share price on 12 April and a 63 per cent...

EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...

Enzymaster raises $45m in Series C round
The Series C financing round was led by Yuanbio Venture Capital with While Bayland Capital, Puhua Capital, C&D Emerging Capital, Hansoh...

Transine Therapeutics Ltd closes £13.7m seed financing
Transine Therapeutics stressed it will use the proceeds to accelerate its preclinical pipeline of novel therapeutic RNAs (SINEUPs) capable of...

Biotalys’ first proteinbased biocontrol shows up in vineyards
Biotalys, the agricultural Technology (AgTech) company in Ghent (Belgium) and listed at EURONEXT (Euronext - BTLS) is devolping protein-based...

XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...

BIONtech breaks ground for manufacturing site in Rwanda
According to BioNtech, the facility will be initially equipped with two BioNTainers, and is expected to employ about 100 staff by 2024. However, the...